nice!_老虎社区_美港股上老虎

acyilin
2021-07-08

nice!

Keymed Makes Hong Kong Debut, Raises $378 million

Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and

Keymed Makes Hong Kong Debut, Raises $378 million

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":143980829,"tweetId":"143980829","gmtCreate":1625755512261,"gmtModify":1633937632497,"author":{"id":3579911378800254,"idStr":"3579911378800254","authorId":3579911378800254,"authorIdStr":"3579911378800254","name":"acyilin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>nice!</p></body></html>","htmlText":"<html><head></head><body><p>nice!</p></body></html>","text":"nice!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/143980829","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"tweetType":1,"viewCount":144,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}